FRAMINGHAM, Mass., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTC-BB:ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical devices, today announced a study of its proprietary adaptive self-assembling barrier scaffold (aSABS) and peptide technology, AC5® Advanced Wound System, demonstrated marked clinical benefit in patients with significant comorbidities and nonhealing wounds. The results of the study were published in the January 2022 issue of the peer-reviewed WOUNDS journal. The manuscript is currently available online here and is expected to be available in physical form later this month.
Clinical Evaluation Finds Arch Therapeutics’ AC5® Advanced Wound System Effective in Healing Complex Chronic Wounds in Patients with Previously Unsuccessful Treatments and Significant Comorbidities
Globe Newswire - Press Release
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
/Super%20Micro%20Computer%20Inc%20logo%20on%20building-by%20Poetra_RH%20via%20Shutterstock.jpg)
/The%20logo%20for%20The%20Trade%20Desk%20displayed%20on%20a%20smartphone%20screen%20by%20Mamun_Sheikh%20via%20Shutterstock.jpg)